November 22, 2021 5:29pm

Pre-open indication results: 4 HITs, 6 MISS

The Biostage (BSTG) Chronicles: Monday closed down -$0.30 to $2.30 with 1,141 shares traded after Friday’s -$0.39 with 8,625 shares traded following Thursday’s flat with 17 shares traded. When are they going to admit they are a failing equity and do something about the current management?

Who else is tracking a broad representative of cell and gene therapy equities – with facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public markets investor to a journalist and pundit; it is that your life and your bank account are largely tied to your questioning of price targets.

 

The Dow closed UP +17.27 points (+0.05%); the S&P closed DOWN -15.02 points (-0.32%) while the Nasdaq closed DOWN -202.68 points (1.26%)

 

Henry’omics:

Indexes collapsed on Monday, reversing an earlier rally that came after President Biden announced he would renominate Jerome Powell to continue to lead the Fed over Fed Governor Lael Brainard.

  • Brainard, was favored by progressives for her stances on bank regulation and climate change, is being nominated for a vice chair position but not to the top regulatory role many had expected.

Since 1950, the last five trading days of November have been traditionally positive. Meanwhile, there’s a two-thirds likelihood the market is up on the day before Thanksgiving Day and a 57% chance the day after the holiday. <Sam Stovall, chief investment strategist at CFRA>

U.S. markets will be closed Thursday on Thanksgiving Day. The stock market closes early at 1 p.m. ET on Friday.

Pains and gains:

  • Precigen (PGEN) reached a 52-week low of $3.60 and has dived further -$0.03
  • Cellectis SA (CLLS) reached a 52-week low of $8.63 and has dived further -$0.10
  • CRISPR Therapeutics (CRSP) reached a 52-week low of $81.08 and added +$0.30

 

Note:

Moderna (MRNA) shares continued their upward momentum, rising +$18.91 or 7.17% to $282.69 in early trading after the FDA last week cleared the company’s booster shot for all U.S. adults.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …

  • Monday opened negative at 6 ups/27 downs, 1 flat and 1 acquired, stayed negative at the mid-day at 7/26, 1 flat and 1 acquired, ending with a negative close of 6/28 and 1 acquired;
  • Friday opened negative at 13 ups/18 downs, 3 flats and 1 acquired, stayed negative at the mid-day at 16/18 and 1 acquired, ending with a negative close of 12 ups/22 downs, 1 flat and 1 acquired;

 

RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: if going to sell, wait for a strengthening. The escape begins to a shortened holiday week, U.S. markets will be closed Thursday on Thanksgiving Day. The stock market closes early at 1 p.m. ET on Friday.” … https://www.regmedinvestors.com/articles/12193

 

Pre-open indication results: 4 HITs: < AxoGen (AXGN +$0.35), Biostage (BSTG -$0.30); Ultragenyx (RARE -$1.70), Applied Genetic Technologies (AGTC - $0.13), > and 6 MISS < bluebird bio (BLUE -$0.16), CRISPR Therapeutics (CRSP -$1.85), Global Blood Therapeutics (GBT -$1.06), Intellia Therapeutics (NTLA -$4.78), Regenxbio (RGNX +$0.21), Sangamo Therapeutics (SGMO -$0.15)>  

 

The Biostage (BSTG) Chronicles: Monday closed down again -$0.30 with 1,141 shares traded after Friday's -$0.39 to $2.60 with 8,625 shares traded after Thursday closed with 17 shares traded, Wednesday closed flat $0.00 with 2,889 shares traded, Tuesday’s +$0.39 with 2,687 shares traded following Monday closed flat with 35 shares traded after Friday with 0 shares traded. Where is the SEC and Nasdaq monitoring?

  • WHY pump the share price with NO clinical trial from a one (1) and 3/4-year-old IND and a negligence rejection of reimbursement in a terminal death suit.
  • What’s there to invest in, the “Sword of Damocles” hanging over the companies non-going operations?

 

Key Metric - volume

Sector volume HIGHER with 4 of the 6-upside having higher than the 3-month average volume with INCREASING volume of 15 of 28-downside having higher than the 3-month average volume;

Outstanding Upside Volume:

  • Athersys (ATHX) closed up +$0.09 with 3,509 m shares traded after Friday’s -$0.125 with 1.382 shares traded after Thursday’s 4.424 shares traded

Outstanding Downside Volume:

  • bluebird bio (BLUE) closed down -$0.16 with 2.312 m shares traded

 

There are clear winners and losers

Jumping with share pricing momentum (6 of 6):

  • Alnylam Pharmaceuticals (ALNY +$6.01 after Friday’s +$2.02),
  • ReNeuron (RENE.L +$1.00 after Friday’s +$1.50),
  • AxoGen (AXGN +$0.35 after Friday’s -$0.37),
  • Regenxbio (RGNX +$0.21 after Friday’s +$1.51),
  • Athersys (ATHX +$0.095),
  • Mesoblast (MESO +$0.01),

Hammered in today’s market (10 of 28):

  • BioLife Solutions (BLFS -$5.25 after Friday’s -$1.20),
  • Intellia Therapeutics (NTLA -$4.78),
  • Vericel (VCEL -$3.77 after Friday’s +$1.67),
  • Fate Therapeutics (FATE -$3.52 after Friday’s +$0.97),
  • Ultragenyx (RARE -$01.70 after Friday’s +$1.93),
  • Editas Medicine (EDIT -$1.49 after Friday’s -$0.92),
  • Ionis Pharmaceuticals (IONS -$1.34),
  • Global Blood Therapeutics (GBT -$1.06 after Friday’s -$1.06),
  • Sage Therapeutics (SAGE -$0.99 after Friday’s +$0.15),
  • uniQure NV (QURE -$0.82 after Friday’s +$0.39),

Closing Flat:

  • 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -0.57% and XBI closed down -2.17%
  • Friday, the IBB closed up +0.57% and XBI closed down -0.25%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +1.26 points or +7.04% at 19.17
  • Friday was up +0.32 points or +1.82% at 17.91

 

November, the second month of Q4/21:

Monday (11/22) closed negative with 6 incliners, 28 decliners and 1 acquired

Friday closed negative with 12 incliners, 22 decliners and 1 acquired

 

The BOTTOM LINE:  What has changed, another cratering session (this week) following yet another whipsaw week beginning.

Reiterating, “the stem, cell and gene therapy sector is morbid and gloomy, with a broad-based decline. Now, the sector is a bit like someone who has gorged on junk food, puked and vomited.”

Relative strength has fallowed during the recent stock market weakness – I’m NOT seeing many just a few!

Investors are sitting out these sessions as electronic trading and algorithms do most of the damage; be cautious about substantially adding exposure, especially in sector names.

  • Q3 earnings reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.